United States - English - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - anastrozole 1 mg - ​1.1 adjuvant treatment anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 first-line treatment anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 second-line treatment anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. 4.1 pregnancy and premenopausal women anastrozole may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. anastrozole is contraindicated in women who are or may become pregnant. there are no adequate and well-controlled studies in pregnant women using a

Israel - English - Ministry of Health

inovamed ltd - anastrozole - film coated tablets - anastrozole 1 mg - anastrozole - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

United States - English - NLM (National Library of Medicine)

ascend laboratories, llc - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - anastrozole 1 mg - 1. indications and usage 1.1. adjuvant treatment     anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2. first-line treatment     anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3. second-line treatment     anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. 4 contraindications 4.1. pregnancy and premenopausal women     anastrozole tablets may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. anastrozole tablets are contraindicated in women who are or may

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - anastrozole 1 mg - enter section text here anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. enter section text here anastrozole tablets may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. anastrozole tablets are contraindicated in women who are or may become pregnant. there are no adequate and well controlled studies in pregnant women using anastrozole tablets. if anastrozole tab

United States - English - NLM (National Library of Medicine)

boscogen, inc. - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - anastrozole 1 mg - 1.1 adjuvant treatment anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. anastrozole is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with  disease progression following tamoxifen therapy.  patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole. 4.1 pregnancy and premenopausal women anastrozole may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer.  anastrozole is contraindicated in women who are or may become pregnant. there are no adequate and well- controlled studies in pregnant women using anastrozole. if anastrozole is used during pregnancy, or if the patient

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - anastrozole -

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - anastrozole 1mg - film coated tablet - 1 mg - active: anastrozole 1mg excipient: hypromellose lactose monohydrate magnesium stearate opadry white y-1-7000 povidone sodium starch glycolate - treatment of advanced breast cancer in post-menopausal women.

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - anastrozole - film coated tablet - 1 milligram - anastrozole

Malta - English - Medicines Authority

accord healthcare limited - anastrozole - film-coated tablet - anastrozole 1 mg - endocrine therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - anastrozole, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; magnesium stearate; sodium starch glycollate type a; hypromellose; titanium dioxide; macrogol 300 - early breast cancer: . adjuvant treatment of early breast cancer in postmenopausal women with oestrogen/progesterone-receptor-positive disease. . advanced breast cancer :. first line treatment of advanced breast cancer in postmenopausal women with oestrogen/progesterone-receptor-positive disease. . treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with oestrogen-receptor-negative disease and patients who have not responded to previous tamoxifen therapy rarely respond to anastrozole.